Ezra Hahn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ezra Hahn has a total of 244 co-authors. Here are the top co-authors by number of shared publications:
- Shao Hui Huang
Princess Margaret Cancer Centre/University of Toronto, Toronto, ON, Canada
14 shared publications Ali Hosni
7 shared publications- Brian O'Sullivan
Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada
7 shared publications - Scott Victor Bratman
Princess Margaret Cancer Center, University Health Network
7 shared publications Jie Su
Department of Biostatistics The Princess Margaret Cancer Centre, University of Toronto Toronto Canada
6 shared publications- John R. de Almeida
Temerty Faculty of Medicine University of Toronto Toronto Ontario Canada
6 shared publications
Latest Publications
- 13 September 2026
- Published by Elsevier in Oral Oncology
- Vol. 182
Validation of the ninth edition pathological and clinical TNM classifications for salivary gland carcinoma
- 13 September 2026
- Published by Elsevier in Oral Oncology
- Vol. 182
Validation of the ninth edition pathological and clinical TNM classifications for salivary gland carcinoma
- 26 August 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (9) , 898
Quality assurance and improvement in dental oncology
- 26 August 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (9) , 898
Quality assurance and improvement in dental oncology
- 8 June 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 125 (3) , 686
Common Scents: The Rationale for Preoperative Radiation in Esthesioneuroblastoma
- 8 June 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 125 (3) , 686
Common Scents: The Rationale for Preoperative Radiation in Esthesioneuroblastoma
- Open Access
- 6 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101164
The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial
- 6 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101164
Open AccessThe role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial
- 27 February 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 219, 111457
Integrity of delivered dose in temporally fractionated lattice radiotherapy amid anatomical changes and setup uncertainties
- 27 February 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 219, 111457
Integrity of delivered dose in temporally fractionated lattice radiotherapy amid anatomical changes and setup uncertainties
- Open Access
- 7 February 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (6) , 2605-2613
Prognostic Value of Impaired Vocal Cord Mobility in T2N0 Glottic Cancer Treated With IMRT
Objectives: To evaluate the prognostic importance of impaired vocal cord mobility (VCM) in T2N0 glottic cancer. Methods: All patients with T2N0 glottic cancer treated with partial laryngeal IMRT in 2009–2021 in our institution were retrospectively reviewed. For comparison, cohorts with T1N0 and T3N0 disease were also included. Locoregional failure (LRF), disease‐free survival (DFS), and overall survival (OS) were compared among T1N0, T2N0 with normal VCM (T2‐Normal‐VCM), T2N0 with impaired VCM (T2‐Impaired‐VCM), and T3N0 groups. Multivariable analysis (MVA) assessed the prognostic value of VCM within the T2N0 group. Results: A total of 642 cases were included: 288 T1N0, 224 T2N0 (147 T2‐Normal‐VCM, 77 T2‐Impaired‐VCM), and 130 T3N0. Median follow‐up was 5.0 years (IQR 3.4–6.2). Five‐year LRF for T1N0, T2‐Normal‐VCM, T2‐Impaired‐VCM, and T3N0 were 4% (95% CI 2–6), 9% (5–15), 27% (17–38), and 35% (27–44), respectively. Corresponding DFS was 83% (78–88), 80% (73–87), 55% (45–68), and 50% (41–60), while OS was 85% (80–90), 86% (80–92), 71% (61–83), and 59% (50–69), respectively. In T2N0, MVA confirmed that impaired VCM was associated with higher LRF (aHR 3.72 [95% CI 1.79–7.71], p < 0.001), lower DFS (aHR 2.74 [1.68–4.45], p < 0.001), and lower OS (aHR 2.07 [1.17–3.67], p = 0.013). Conclusions: In this contemporary cohort, LRF rates increased stepwise from T1N0 to T2‐Normal‐VCM, T2‐Impaired‐VCM, and T3N0 glottic cancer. Within T2N0 disease, impaired VCM is an adverse prognostic factor, supporting subdivision into T2a (normal VCM) and T2b (impaired VCM) in future TNM revisions. Prospective studies are warranted to assess whether treatment intensification can improve outcomes for T2‐Impaired‐VCM disease. Level of Evidence: 3.
- 7 February 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (6) , 2605-2613
Open AccessPrognostic Value of Impaired Vocal Cord Mobility in T2N0 Glottic Cancer Treated With IMRT
Objectives: To evaluate the prognostic importance of impaired vocal cord mobility (VCM) in T2N0 glottic cancer. Methods: All patients with T2N0 glottic cancer treated with partial laryngeal IMRT in 2009–2021 in our institution were retrospectively reviewed. For comparison, cohorts with T1N0 and T3N0 disease were also included. Locoregional failure (LRF), disease‐free survival (DFS), and overall survival (OS) were compared among T1N0, T2N0 with normal VCM (T2‐Normal‐VCM), T2N0 with impaired VCM (T2‐Impaired‐VCM), and T3N0 groups. Multivariable analysis (MVA) assessed the prognostic value of VCM within the T2N0 group. Results: A total of 642 cases were included: 288 T1N0, 224 T2N0 (147 T2‐Normal‐VCM, 77 T2‐Impaired‐VCM), and 130 T3N0. Median follow‐up was 5.0 years (IQR 3.4–6.2). Five‐year LRF for T1N0, T2‐Normal‐VCM, T2‐Impaired‐VCM, and T3N0 were 4% (95% CI 2–6), 9% (5–15), 27% (17–38), and 35% (27–44), respectively. Corresponding DFS was 83% (78–88), 80% (73–87), 55% (45–68), and 50% (41–60), while OS was 85% (80–90), 86% (80–92), 71% (61–83), and 59% (50–69), respectively. In T2N0, MVA confirmed that impaired VCM was associated with higher LRF (aHR 3.72 [95% CI 1.79–7.71], p < 0.001), lower DFS (aHR 2.74 [1.68–4.45], p < 0.001), and lower OS (aHR 2.07 [1.17–3.67], p = 0.013). Conclusions: In this contemporary cohort, LRF rates increased stepwise from T1N0 to T2‐Normal‐VCM, T2‐Impaired‐VCM, and T3N0 glottic cancer. Within T2N0 disease, impaired VCM is an adverse prognostic factor, supporting subdivision into T2a (normal VCM) and T2b (impaired VCM) in future TNM revisions. Prospective studies are warranted to assess whether treatment intensification can improve outcomes for T2‐Impaired‐VCM disease. Level of Evidence: 3.
- 22 November 2025
- Published by Elsevier in Oral Oncology
- Vol. 171, 107794
Outcomes and characteristics of patients receiving pre-operative versus post-operative radiotherapy for sinonasal squamous cell carcinoma
- 22 November 2025
- Published by Elsevier in Oral Oncology
- Vol. 171, 107794
Outcomes and characteristics of patients receiving pre-operative versus post-operative radiotherapy for sinonasal squamous cell carcinoma
- Open Access
- 15 November 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 11 (2) , 101948
Clinical Outcomes and Institutional Experience of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer
- 15 November 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 11 (2) , 101948
Open AccessClinical Outcomes and Institutional Experience of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer
- Open Access
- 3 September 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 50, 101218
Risk factors and survival impact of severe radiation-related late toxicities in head and neck cancer–a cohort study
- 3 September 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 50, 101218
Open AccessRisk factors and survival impact of severe radiation-related late toxicities in head and neck cancer–a cohort study